vs
Axos Financial, Inc.（AX）与Embecta Corp.（EMBC）财务数据对比。点击上方公司名可切换其他公司
Axos Financial, Inc.的季度营收约是Embecta Corp.的1.5倍（$392.2M vs $261.2M），Axos Financial, Inc.净利率更高（31.8% vs 16.9%，领先14.9%），过去两年Axos Financial, Inc.的营收复合增速更高（16.1% vs -4.6%）
Axos Financial是总部位于美国内华达州拉斯维加斯的银行控股公司，旗下拥有直销银行Axos Bank，同时提供注册投资顾问服务及电子交易平台，深耕数字化金融赛道，可为用户提供多元便捷的金融服务解决方案。
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
AX vs EMBC — 直观对比
营收规模更大
AX
是对方的1.5倍
$261.2M
净利率更高
AX
高出14.9%
16.9%
两年增速更快
AX
近两年复合增速
-4.6%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $392.2M | $261.2M |
| 净利润 | $124.7M | $44.1M |
| 毛利率 | — | 61.9% |
| 营业利润率 | — | 31.9% |
| 净利率 | 31.8% | 16.9% |
| 营收同比 | — | -0.3% |
| 净利润同比 | 18.5% | — |
| 每股收益（稀释后） | $2.15 | $0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXEMBC
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $261.2M | ||
| Q3 25 | $323.4M | $264.0M | ||
| Q2 25 | $321.4M | $295.5M | ||
| Q1 25 | $308.8M | $259.0M | ||
| Q4 24 | $307.9M | $261.9M | ||
| Q3 24 | $320.7M | $286.1M | ||
| Q2 24 | $290.9M | $272.5M |
净利润AXEMBC
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $44.1M | ||
| Q3 25 | $112.4M | $26.4M | ||
| Q2 25 | $110.7M | $45.5M | ||
| Q1 25 | $105.2M | $23.5M | ||
| Q4 24 | $104.7M | $0 | ||
| Q3 24 | $112.3M | $14.6M | ||
| Q2 24 | $104.9M | $14.7M |
毛利率AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | — | 61.9% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | 66.7% | ||
| Q1 25 | — | 63.4% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | — | 60.7% | ||
| Q2 24 | — | 69.8% |
营业利润率AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | 31.9% | ||
| Q3 25 | 46.3% | 21.4% | ||
| Q2 25 | 48.5% | 31.8% | ||
| Q1 25 | 47.9% | 24.3% | ||
| Q4 24 | 48.8% | 11.0% | ||
| Q3 24 | 49.6% | 9.2% | ||
| Q2 24 | 49.6% | 20.5% |
净利率AXEMBC
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | 16.9% | ||
| Q3 25 | 34.7% | 10.0% | ||
| Q2 25 | 34.4% | 15.4% | ||
| Q1 25 | 34.1% | 9.1% | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 35.0% | 5.1% | ||
| Q2 24 | 36.0% | 5.4% |
每股收益（稀释后）AXEMBC
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $0.74 | ||
| Q3 25 | $1.94 | $0.44 | ||
| Q2 25 | $1.89 | $0.78 | ||
| Q1 25 | $1.81 | $0.40 | ||
| Q4 24 | $1.80 | $0.00 | ||
| Q3 24 | $1.93 | $0.24 | ||
| Q2 24 | $1.75 | $0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $201.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.1B | $-613.1M |
| 总资产 | $29.2B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $201.3M | ||
| Q3 25 | $2.6B | $225.5M | ||
| Q2 25 | $1.9B | $230.6M | ||
| Q1 25 | $2.0B | $209.3M | ||
| Q4 24 | $2.4B | $210.0M | ||
| Q3 24 | $2.6B | $267.5M | ||
| Q2 24 | $2.0B | $275.1M |
总债务AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $312.7M | — | ||
| Q1 25 | $377.4M | — | ||
| Q4 24 | $358.7M | — | ||
| Q3 24 | $313.5M | $1.6B | ||
| Q2 24 | $325.7M | — |
股东权益AXEMBC
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $-613.1M | ||
| Q3 25 | $2.8B | $-650.6M | ||
| Q2 25 | $2.7B | $-669.6M | ||
| Q1 25 | $2.6B | $-736.2M | ||
| Q4 24 | $2.5B | $-768.8M | ||
| Q3 24 | $2.4B | $-738.3M | ||
| Q2 24 | $2.3B | $-763.7M |
总资产AXEMBC
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $1.1B | ||
| Q3 25 | $27.4B | $1.1B | ||
| Q2 25 | $24.8B | $1.2B | ||
| Q1 25 | $24.0B | $1.1B | ||
| Q4 24 | $23.7B | $1.1B | ||
| Q3 24 | $23.6B | $1.3B | ||
| Q2 24 | $22.9B | $1.3B |
负债/权益比AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $17.2M |
| 自由现金流经营现金流 - 资本支出 | — | $16.6M |
| 自由现金流率自由现金流/营收 | — | 6.4% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | 0.39× |
| 过去12个月自由现金流最近4个季度 | — | $205.8M |
8季度趋势，按日历期对齐
经营现金流AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $17.2M | ||
| Q3 25 | $118.4M | $84.0M | ||
| Q2 25 | $490.3M | $81.2M | ||
| Q1 25 | $73.7M | $31.8M | ||
| Q4 24 | $162.5M | $-5.3M | ||
| Q3 24 | $70.8M | $26.6M | ||
| Q2 24 | $305.5M | $-2.1M |
自由现金流AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | $85.4M | $16.6M | ||
| Q3 25 | $109.3M | $76.7M | ||
| Q2 25 | $436.1M | $80.8M | ||
| Q1 25 | $65.1M | $31.7M | ||
| Q4 24 | $156.4M | $-6.8M | ||
| Q3 24 | $53.0M | — | ||
| Q2 24 | $269.5M | $-11.8M |
自由现金流率AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | 22.2% | 6.4% | ||
| Q3 25 | 33.8% | 29.1% | ||
| Q2 25 | 135.7% | 27.3% | ||
| Q1 25 | 21.1% | 12.2% | ||
| Q4 24 | 50.8% | -2.6% | ||
| Q3 24 | 16.5% | — | ||
| Q2 24 | 92.6% | -4.3% |
资本支出强度AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 0.2% | ||
| Q3 25 | 2.8% | 2.8% | ||
| Q2 25 | 16.9% | 0.1% | ||
| Q1 25 | 2.8% | 0.0% | ||
| Q4 24 | 2.0% | 0.6% | ||
| Q3 24 | 5.5% | 0.0% | ||
| Q2 24 | 12.4% | 3.6% |
现金转化率AXEMBC
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | 0.39× | ||
| Q3 25 | 1.05× | 3.18× | ||
| Q2 25 | 4.43× | 1.78× | ||
| Q1 25 | 0.70× | 1.35× | ||
| Q4 24 | 1.55× | — | ||
| Q3 24 | 0.63× | 1.82× | ||
| Q2 24 | 2.91× | -0.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
